Crew Capital Management Ltd. Acquires Shares of 13,819 Gilead Sciences, Inc. (NASDAQ:GILD)

Crew Capital Management Ltd. bought a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 13,819 shares of the biopharmaceutical company's stock, valued at approximately $1,159,000. Gilead Sciences makes up approximately 0.9% of Crew Capital Management Ltd.'s holdings, making the stock its 23rd biggest holding.

A number of other institutional investors have also recently made changes to their positions in the business. Manning & Napier Advisors LLC purchased a new stake in shares of Gilead Sciences in the second quarter valued at $25,328,000. Legal & General Group Plc lifted its stake in Gilead Sciences by 0.8% in the second quarter. Legal & General Group Plc now owns 12,414,268 shares of the biopharmaceutical company's stock worth $851,743,000 after purchasing an additional 93,068 shares during the last quarter. GSA Capital Partners LLP purchased a new position in shares of Gilead Sciences during the first quarter valued at approximately $462,000. Brookstone Capital Management grew its stake in shares of Gilead Sciences by 751.1% during the first quarter. Brookstone Capital Management now owns 127,258 shares of the biopharmaceutical company's stock valued at $9,322,000 after buying an additional 112,305 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC raised its holdings in shares of Gilead Sciences by 13.1% in the second quarter. Wealth Enhancement Advisory Services LLC now owns 286,116 shares of the biopharmaceutical company's stock worth $19,630,000 after buying an additional 33,162 shares during the period. Institutional investors own 83.67% of the company's stock.

Gilead Sciences Stock Down 0.5 %

Shares of GILD traded down $0.43 during midday trading on Monday, hitting $86.29. 4,451,152 shares of the company's stock traded hands, compared to its average volume of 7,067,366. The company has a current ratio of 1.14, a quick ratio of 0.95 and a debt-to-equity ratio of 1.18. The stock has a market capitalization of $107.50 billion, a price-to-earnings ratio of 239.69, a price-to-earnings-growth ratio of 2.98 and a beta of 0.18. Gilead Sciences, Inc. has a 1 year low of $62.07 and a 1 year high of $87.86. The firm's fifty day moving average is $81.32 and its 200-day moving average is $72.94.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, topping the consensus estimate of $1.61 by $0.40. Gilead Sciences had a return on equity of 29.34% and a net margin of 3.79%. The business had revenue of $6.95 billion during the quarter, compared to the consensus estimate of $6.64 billion. As a group, sell-side analysts anticipate that Gilead Sciences, Inc. will post 3.78 earnings per share for the current year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, September 27th. Stockholders of record on Friday, September 13th were paid a dividend of $0.77 per share. The ex-dividend date was Friday, September 13th. This represents a $3.08 annualized dividend and a dividend yield of 3.57%. Gilead Sciences's payout ratio is currently 855.56%.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the company. BMO Capital Markets upped their price objective on Gilead Sciences from $85.00 to $94.00 and gave the company an "outperform" rating in a research report on Thursday. Truist Financial lifted their price objective on shares of Gilead Sciences from $82.00 to $83.00 and gave the company a "hold" rating in a report on Thursday, August 15th. Raymond James upgraded shares of Gilead Sciences from a "market perform" rating to an "outperform" rating and set a $93.00 target price on the stock in a research note on Monday, July 8th. Leerink Partners raised shares of Gilead Sciences from a "market perform" rating to an "outperform" rating and lifted their price target for the company from $74.00 to $96.00 in a research note on Monday. Finally, Wells Fargo & Company upgraded Gilead Sciences from an "equal weight" rating to an "overweight" rating and boosted their price target for the company from $78.00 to $100.00 in a report on Monday, October 7th. Ten research analysts have rated the stock with a hold rating, eleven have issued a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, Gilead Sciences presently has an average rating of "Moderate Buy" and a consensus target price of $86.85.

Insider Activity

In other news, insider Merdad Parsey sold 2,000 shares of the stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $83.83, for a total value of $167,660.00. Following the transaction, the insider now directly owns 100,189 shares of the company's stock, valued at approximately $8,398,843.87. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, insider Merdad Parsey sold 2,000 shares of the company's stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $83.83, for a total value of $167,660.00. Following the sale, the insider now directly owns 100,189 shares of the company's stock, valued at $8,398,843.87. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Johanna Mercier sold 29,357 shares of the firm's stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $83.78, for a total transaction of $2,459,529.46. Following the transaction, the insider now directly owns 78,127 shares of the company's stock, valued at approximately $6,545,480.06. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 36,847 shares of company stock valued at $3,033,340 over the last ninety days. 0.16% of the stock is currently owned by insiders.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.